Please assess the completion status of the following clinical trial:

Trial Title: PP100-01 (Calmangafodipir) for Overdose of Paracetamol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Any patient with capacity admitted to hospital within 24 hrs either a single acute POD or more than one dose of paracetamol (staggered) and deemed to require treatment with NAC.~2. Provision of written informed consent~3. Males and females of at least 16 years of age~Exclusion Criteria:~1. Patients that do not have the capacity to consent to participate in the study~2. Patients detained under the Mental Health Act or deemed unfit by the Investigator to participate due to mental health.~3. Patients with known permanent cognitive impairment~4. Patients who are pregnant or nursing~5. Patients who have previously participated in the study~6. Unreliable history of POD~7. Patients presenting after 24hrs of POD~8. Patients who take anticoagulants (e.g. warfarin) therapeutically or have taken an overdose of anticoagulants~9. Patients who, in the opinion of the responsible clinician/nurse, are unlikely to complete the full course of NAC e.g. expressing wish to self-discharge~10. Prisoners~11. Non-English speaking patients. (Study information material will only be produced in English in view of the known and stable demographic of the Edinburgh self-harm population).

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acetylcysteine (N-acetylcysteine; NAC) (Type: NO_INTERVENTION): NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.
- PP100-01 (Calmangafodipir)+ NAC (Type: EXPERIMENTAL): In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:~* Group A: PP100-01 (2 umol/kg calmangafodipir) after the loading dose of NAC~* Group B: PP100-01 (5 umol/kg calmangafodipir) after the loading dose of NAC~* Group C: PP100-01 (10 umol/kg calmangafodipir) after the loading dose of NAC~PP100-01 treatment is administered intravenously over 5 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).